Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
Anna W Chalmers, Jamile M Shammo Department of Internal Medicine, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA Abstract: Transfusion-dependent anemia is a common feature in a wide array of hematological disorders, including thalassemia, sickle cell disease, aplas...
Saved in:
Main Authors: | Chalmers AW (Author), Shammo JM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on the use of deferasirox in the management of iron overload
by: Ali Taher, et al.
Published: (2009) -
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018) -
Switching from Deferasirox Dispersible Tablets to Deferasirox Film-Coated Tablets: Is There an Effect on Ferritin Levels in Children and Adolescents with Transfusion-Dependent Anemia?
by: Esra Arslantaş, et al.
Published: (2024) -
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
by: Kontoghiorghe CN, et al.
Published: (2016) -
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015)